Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
了解更多
How Luminex Is Supporting Research Partners’ Pandemic Response
Licensed Technologies Group is finding new ways to boost partner programs
Our Licensed Technologies Group (LTG), which works closely with our many research partners to help develop assays and services based on xMAP® Technology, has pivoted to be more involved in coronavirus efforts. Employees in this area are used to traveling all the time to visit partners. Now, the whole team is working from home and finding new ways to help colleagues in other organizations who are involved in characterizing the COVID-19 immune response, studying disease progression, developing serology tests or vaccine candidates, and more.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
May 22nd
Luminex Corporation Declares Second Quarter Cash Dividend
May 4th
Luminex Corporation Reports First Quarter 2020 Results
April 22nd
Luminex Corporation First Quarter Earnings Release Rescheduled for May 4, 2020
Coronavirus Virtual Webinar Series
June 17th
Virtual
International Society for Extracellular Vesicles (ISEV) Annual Meeting
July 20-22
Virtual
